769 patents
Page 7 of 39
Utility
Methods of Treating an Inflammatory or Obstructive Airway Disease Using Anti-tslp Antibody
16 Mar 23
The present disclosure relates to methods, treatment regimens, uses, kits, compositions and medicaments for treating an inflammatory or obstructive airway disease, such as asthma, including severe asthma, or COPD, by employing an anti-TSLP antibody or anti-TSLP antibody fragment.
Ankur AJMERA, Jürgen DEDERICHS, Sarah Schmidt GRANT, Kristin HENSON, Monish JAIN, Sandro PAGANI, Yinuo PANG, Marianna ROWLANDS
Filed: 28 Jan 21
Utility
Process for Concentration of Antibodies and Therapeutic Products Thereof
9 Mar 23
This present disclosure provides a process for concentrating proteins including an ultrafiltering, a diafiltering, and a second ultrafiltering sequence, at elevated temperatures, such as above about 30° C.
Charles M. WINTER
Filed: 1 Nov 22
Utility
Crystalline Forms of N-[4-(CHLORODIFLUOROMETHOXY)PHENYL]-6-[(3R)-3-HYDROXYPYRROLIDIN-1-YL]-5-(1H-PYRAZOL-5-YL)PYRIDINE-3-CARBOXAMIDE
9 Mar 23
The present invention describes specific crystalline forms of N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide.
Stephanie Kay DODD, Arnaud GRANDEURY, Emmanuel SUFFERT, Evgenia ROUSAKI
Filed: 6 Jul 22
Utility
Car-t Cell Therapies with Enhanced Efficacy
9 Mar 23
The invention provides compositions and methods for treating diseases such as cancer.
Shelley L. Berger, Katherine Ann Alexander, Sierra Marie McDonald
Filed: 20 Mar 20
Utility
Variant CD58 Domains and Uses Thereof
9 Mar 23
The present disclosure provides CD2 binding molecules that specifically bind to CD2, including monospecific, bispecific and trispecific binding molecules, conjugates comprising the CD2 binding molecules, and pharmaceutical compositions comprising the CD2 binding molecules and the conjugates.
Barbara BRANNETTI, Dattananda CHELUR, Brian GRANDA, Connie HONG
Filed: 19 May 20
Utility
Compositions and Methods for Selective Protein Expression
9 Mar 23
Provided herein are fusion proteins including two protein domains separated by a heterologous protease cleavage site, wherein a first of the protein domains is a conditional expression domain.
Andrei Golosov, Carla Patricia Pinto Guimaraes, Gregory Motz, Michael C. Milone, Christoph T. Ellebrecht, Aimee S. Payne
Filed: 14 Apr 17
Utility
Compounds and Compositions for Treating Conditions Associated with NLRP Activity
2 Mar 23
Luigi FRANCHI, Shomir GHOSH, Gary GLICK, Jason KATZ, Anthony William OPIPARI, JR., William ROUSH, Hans Martin SEIDEL, Dong-Ming SHEN, Shankar VENKATRAMAN, David Guenther WINKLER
Filed: 7 Oct 21
Utility
Dosing schedule of a Wnt inhibitor and an anti-PD-1 antibody molecule in combination
2 Mar 23
The present disclosure relates to the field of pharmacy, particularly to a Wnt inhibitor and a PD-1 inhibitor for use in the treatment of cancer.
Jason Russell Dobson, Susan Moody, Margaret Elise McLaughlin
Filed: 29 Jun 22
Utility
Sulfonimidamide Compounds and Compositions for Treating Conditions Associated with NLRP Activity
2 Mar 23
In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: (Formula AA) or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.
Jason KATZ, William R. ROUSH, Hans Martin SEIDEL, Dong-Ming SHEN, Shankar VENKATRAMAN
Filed: 23 Jan 20
Utility
Combination Treatment of Liver Diseases Using Integrin Inhibitors
2 Mar 23
The invention provides a pharmaceutical combination including an αvβ1 integrin inhibitor and at least one additional therapeutic agent for preventing, delaying or treating liver diseases or disorders.
Kraig ANDERSON, Christopher BAILEY, Avirup BOSE, Jacob CHA, Nicole COOPER, Darren FINKELSTEIN, Linda GREENBAUM, Johannes HULL, Susan Caroline KIRKLAND, Katerina LEFTHERIS, Maureen REILLY, Peter TARSA, Chinweike UKOMADU
Filed: 18 Dec 20
Utility
3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE Derivatives and Uses Thereof
2 Mar 23
Claire ADCOCK, Simone BONAZZI, Artiom CERNIJENKO, Philip LAM, Kathryn Taylor LINKENS, Hasnain Ahmed MALIK, Noel Marie-France THOMSEN, Michael Scott VISSER
Filed: 8 Nov 21
Utility
Combination Treatment of Liver Diseases Using Integrin Inhibitors
23 Feb 23
The invention provides a pharmaceutical combination including an αvβ1 integrin inhibitor and at least one additional therapeutic agent for preventing, delaying or treating liver diseases or disorders.
Kraig ANDERSON, Christopher BAILEY, Avirup BOSE, Jacob CHA, Nicole COOPER, Darren FINKELSTEIN, Linda GREENBAUM, Johannes HULL, Susan Caroline KIRKLAND, Katerina LEFTHERIS, Maureen REILLY, Peter TARSA, Chinweike UKOMADU
Filed: 18 Dec 20
Utility
Uses of Anti-tgf-beta Antibodies and Checkpoint Inhibitors for the Treatment of Proliferative Diseases
23 Feb 23
Therapies using TGF-β inhibitors and/or PD-1 inhibitors are disclosed.
Mirek DOSTALEK, Claire FABRE, Fariba KHANSHAN
Filed: 3 Dec 20
Utility
Combination of Anti TIM-3 Antibody MBG453 and Anti Tgf-beta Antibody NIS793, with or without Decitabine or the Anti PD-1 Antibody Spartalizumab, for Treating Myelofibrosis and Myelodysplastic Syndrome
23 Feb 23
Combination therapies comprising TIM-3 inhibitors and TGF-β inhibitors are disclosed.
K. Gary J. VANASSE, Haiying SUN, Mirek DOSTALEK, Mikael RINNE, Anshu MARATHE, Luigi MANENTI, Claire FABRE, Fariba KHANSHAN
Filed: 3 Dec 20
Utility
Combination Comprising a TIM-3 Inhibitor and a Hypomethylating Agent for Use In Treating Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
23 Feb 23
Combination therapies comprising TIM-3 inhibitors are disclosed.
Hans MENSSEN, Mikael RINNE, Kamel MALEK
Filed: 15 Jan 21
Utility
the Compounds and Compositions for Treating Conditions Associated with NLRP Activity
23 Feb 23
Luigi FRANCHI, Shomir GHOSH, Gary GLICK, Jason KATZ, Anthony William OPIPARI, Jr., William ROUSH, Hans Martin SEIDEL, Dong-Ming SHEN, Shankar VENKATRAMAN, David Guenther WINKLER
Filed: 14 Nov 19
Utility
Dc-sign Antibody Drug Conjugates
23 Feb 23
Provided herein are antibodies to DC-SIGN, conjugates of DC-SiGN antibodies, and DC-SiGN antibody fusion proteins and the use of such antibodies, conjugates, and fusion proteins for the treatment of diseases such as cancer.
Lisa BARNETT, Steven BENDER, Alex Cortez, Sarah COX, Jonathan DEANE, Scott Martin GLASER, Ben WEN, Tom Yao-Hsiang WU
Filed: 30 Oct 19
Utility
Compositions and Methods for Enhancing Visual Function
16 Feb 23
The present disclosure provides compositions and methods of restoring or enhancing visual function in an individual by administering to the individual a pharmaceutical composition comprising a recombinant adeno-associated viral (rAAV) vector having a polynucleotide sequence that encodes a medium wavelength cone opsin (MW-opsin).
Karen I. Guerin, Robert M. Kotin, Eric Pastor, Xiaozhi Ren, Sharon Young
Filed: 18 May 22
Utility
Compounds and Compositions for Treating Conditions Associated with NLRP Activity
16 Feb 23
Luigi FRANCHI, Shomir GHOSH, Gary GLICK, Jason KATZ, Anthony William OPIPARI, Jr., William ROUSH, Hans Martin SEIDEL, Dong-Ming SHEN, Shankar VENKATRAMAN, David Guenther WINKLER
Filed: 14 Nov 19
Utility
Bicyclic Compounds and their Uses
16 Feb 23
Vincent BORDAS, Jvan BRUN, Andrea DECKER, Markus FUREGATI, Geoffrey GOGNIAT, Wanben GONG, Jacques HAMON, Jürgen Hans-Hermann HINRICHS, Philipp HOLZER, Fatma LIMAM, Henrik MÖBITZ, Sandro NOCITO, Simone PLATTNER, Niko SCHMIEDEBERG, Joseph SCHOEPFER, Jessica SOTO, Ross Sinclair STRANG, Shuping YAO, Huangchao YU, Frédéric ZECRI, Sisi ZHANG
Filed: 25 May 22